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•  Hematology	  department	  (Pr	  Yves	  Beguin)	  
•  best	  clinical	  pra2ce	  to	  GMP	  
•  Clinical	  grade,	  ready	  to	  use,	  third-­‐party	  MSC	  
•  Several	  clinical	  trials	  
	  
•  Clinical	  grade	  Tregs	  for	  future	  trials	  

Active MSC Clinical Trials 
HSCT 
1.  TJB0703: Infusion of MSC as treatment for steroid resistant grade II to IV 
acute GVHD or poor graft function 
2.  TJB0603: Randomized double-blind study of mesenchymal stem cells 
(MSC) in patients undergoing matched unrelated allogeneic bone marrow or 
peripheral blood stem cell transplantation - A European multicentre study 
3.  TJB0909: Co-transplantation of MSC and HLA-mismatched allogeneic 
hematopoietic cell after nonmyeloablative conditioning: a phase II 
randomized double-blind study. 
4.  TJB0905: A pilot study to assess the feasibility of unrelated UCB 
transplantation with coinfusion of third-party MSC after myeloablative or 
non-myeloablative conditioning in adult patients with hematological 
malignancies 
Active MSC Clinical Trials 
Non-HSCT 
 
1.  TJT1106: Infusion of third-party mesenchymal stem cells after renal or liver 
transplantation: a phase I-II, open-label, clinical study 
2.  TJT1123: Mesenchymal stem cell therapy for the treatment of severe or 
refractory inflammatory and/or autoimmune disorders 

Mesenchymal Stem Cells 
MSC: technical aspects 
MSC production 
•  Collect 30-60 ml BM healthy allogeneic volunteers 
•  Day 0: culture initiation (MNC obtained by ficoll isolation): 
DMEM-Glu + 10% FBS + 1% Pen/Strep 
•  2X/week: medium exchange 
•  Day 14: 1st passage  (trypsinisation et replating) 
•  Day 21: 2nd passage   
•  Day 28: Harvest and freezing 
MSC 
  MNC culture initiation 
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Release Criteria 
•  Donor:  
•  Serology, clinical examination and consent 
•  MSC Product : 
•  Sterility 
•  Endotoxins and mycoplasma free 
•  Phenotype : 
•  CD105+, CD90+, CD73+ 
•  CD34-, CD45-, CD14- CD3- 
•  Fibroblastic morphology 
•  No aggregates 
•  Normal karyotypes 
•  Immunosuppressive in vitro 
Inhibition of PBMC proliferation by third party MSC 
PBMC (100,000 or 50,000) were stimulated (S-PBMC) with anti-αCD3/CD28 microbeads during 4 
days with or without irradiated (25 Gy) MSC (10/1 or 5/1 PBMC/MSC ratios) added at the beginning 
of the culture. Proliferation was assessed by analysis of the cell cycle by flow cytometry. Result are 
expressed as the percentage of cells present in S+G2M phases (A) and as the percentage of inhibition 




































































































































50 placebo units 
produced 
18 placebo units 
infused 
31 placebo units 
available 
1 placebo unit 
used for R&D 
•  UCL St Luc Brussel 
•  UZ Brussel  
•  KUL Leuven  
•  UZG Gent  
•  UZA Antwerpen  
•  ZNA  Stuivenberg 
•  AZ St Jan Brugge 
•  UZ Gasthuisberg  
•  Mont-Godinne Yvoir 
•  … 
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Background	  
•  MSC	  may	  have	  an	  immunosuppressive	  effect	  
•  MSC	  may	  be	  used	  in	  GVHD	  aYer	  SCTx	  
•  MSC	  may	  have	  an	  effect	  in	  organ	  regenera2on	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•  Primary	  endpoint:	  safety	  for	  LT	  &	  KT	  recipients	  
-­‐	  tolerability	  of	  infusion	  
-­‐	  infec2ons	  (bacterial,	  viral,	  fungi)	  
-­‐	  cancers	  (PTLD,	  others)	  
-­‐	  pa2ent	  and	  graY	  survivals	  
	  
Objec2ves	  
•  Primary	  endpoint:	  safety	  for	  LT	  &	  KT	  recipients	  
-­‐	  tolerability	  of	  infusion	  
-­‐	  infec2ons	  (bacterial,	  viral,	  fungi)	  
-­‐	  cancers	  (PTLD,	  others)	  
-­‐	  pa2ent	  and	  graY	  survivals	  
	  
•  Secondary	  endpoint	  1:	  immunosuppression	  
-­‐	  rejec2on	  rate	  
-­‐	  biopsy	  
-­‐	  blood	  immune	  profile	  
•  Secondary	  endpoint	  2:	  graY	  func2on	  &	  biopsy	  
M&M	  
•  Cadaveric	  liver	  &	  kidney	  recipients	  
•  Classical	  immunosuppressive	  management	  
•  Dose:	  1.5	  to	  3x106/kg	  MSC	  	  
•  Central	  IV	  injec2on	  at	  day	  3	  +/-­‐2	  post	  Tx	  	  
M&M:	  liver	  1	  
•  Liver	  transplanta2on	  	  
-­‐	  2	  groups:	  	  	  -­‐10	  MSC	  +	  
	   	   	   	  	  	  	  	  -­‐10	  MSC	  -­‐	  
	  
-­‐	  no	  randomisa2on,	  no	  double-­‐blind	  
-­‐	  regular	  immunosupression	  (Tac-­‐MMF-­‐steroids)	  
-­‐	  protocol	  biopsy	  at	  month	  6	  in	  both	  groups	  
	  
•  MSC	  group:	  	  
-­‐	  tapering	  of	  Tac	  from	  month	  6	  to	  9,	  then	  biopsy	  
-­‐	  tapering	  MMF	  from	  month	  9	  to	  12	  	  
M&M:	  liver	  2	  
•  Inclusions:	  	  
-­‐	  liver	  candidates	  between	  18	  to	  75y	  
•  Exclusions:	  
-­‐	  history	  of	  K	  except	  HCC	  within	  Milan	  	  
-­‐	  ac2ve	  infec2on	  (D	  and	  R),	  including	  HCV,	  HIV	  
-­‐	  EBV	  nega2ve	  
-­‐	  reTx,	  combined	  Tx,	  LRLTx	  
-­‐	  autoimmune	  
-­‐	  intuba2on	  
-­‐	  clinical	  problem	  at	  the	  2me	  of	  injec2on	  	  
M&M:	  liver	  3	  
•  Tacrolimus:	  8-­‐12	  for	  one	  month,	  5-­‐8	  aYer	  one	  month	  
•  MMF:	  2x500mg/d	  
•  Steroids:	  	  
-­‐	  Solumedrol:	  500	  mg	  d0,	  125	  mg	  d1,	  80	  mg	  d2,	  40	  mg	  d3	  
-­‐	  Medrol:	  	  
	   	   	  32mg	  d4	  to	  6,	  16mg	  d7	  to	  9,	  	  
	   	   	  8mg	  d10	  to	  12,	  then	  4	  mg	  un2l	  day	  30	  
•  An2bio2cs:	  
cefuroxime	  3x1.5g	  or	  piperacillin-­‐tazobactam	  for	  5	  days	  	  
co-­‐trimoxazole	  500	  mg	  po	  1/d	  for	  three	  months	  	  
CMV	  prophylaxis	  if	  D+/R-­‐	  
M&M:	  kidney	  1	  
•  Kidney	  transplanta2on	  	  
-­‐	  2	  groups:	  	  	  	  	  -­‐10	  MSC	  +	  
	   	   	   	   	  -­‐10	  MSC	  –	  
	  
•  -­‐	  regular	  immunosupression	  (an2IL2-­‐Tac-­‐MMF-­‐steroids)	  
-­‐	  biopsy	  at	  month	  3	  in	  both	  groups	  
-­‐	  weaning	  of	  steroids	  
	  	  
	  
M&M:	  kidney	  2	  
•  Inclusions:	  	  
-­‐	  kidney	  candidates	  between	  18	  to	  75y	  
•  Exclusions:	  
-­‐	  history	  of	  K	  	  
-­‐	  ac2ve	  infec2on	  (D	  and	  R),	  including	  HCV,	  HIV	  
-­‐	  EBV	  nega2ve	  
-­‐	  reTx,	  combined	  Tx,	  LRLTx	  
-­‐	  presumed	  impossibility	  to	  wean	  steroids	  
-­‐	  intuba2on	  
-­‐	  clinical	  problem	  at	  the	  2me	  of	  injec2on	  
-­‐	  PRA	  >50%	  	  
M&M:	  kidney	  3	  
•  An2-­‐IL2	  day	  0	  &	  4	  
•  Tac:	  12-­‐15	  for	  one	  week,	  8-­‐12	  for	  three	  months	  
•  MMF:	  2x1000mg/d	  
•  Steroids:	  	  
-­‐	  Solumedrol:	  500	  mg	  d0,	  125	  mg	  d1	  
-­‐	  Medrol:	  	  
	   	   	  16mg	  d2	  to	  d21	  
	  	  	  	  	  	  	  	  	   	  12mg	  d22	  to	  d42	  
	   	   	  8mg	  d43	  to	  63	  
	   	   	  6	  mg	  d64	  to	  84	  
	   	   	  4mg	  d85	  to	  	  90	  
•  An2bio2cs:	  
cefuroxime	  3x1.5g	  or	  piperacillin-­‐tazobactam	  for	  1	  day	  	  
co-­‐trimoxazole	  500	  mg	  po	  1/d	  for	  three	  months	  	  
CMV	  if	  D+/R-­‐	  
M&M	  
•  Blood:	  FACS,	  Tregs,	  Ig,	  an2-­‐HLA	  
•  Biopsies:	  
-­‐	  Histology	  	  
-­‐	  Immunohistology:	  C4d,	  CD3,	  CD4,	  CD8,	  
CD20,	  CD138,	  CD68,	  CD1a,	  FoxP3,	  CMV,	  EBV,	  
Hbs	  
	  
•  Banking	  of	  serum	  &	  biopsies	  
Update	  
•  Started	  in	  early	  2012	  
	  
•  Liver	  Transplanta2on	  
-­‐	  10	  MSC	  treated,	  10	  controls	  
	  (last	  February	  2014)	  
	  
•  Kidney	  transplanta2on	  
-­‐	  4	  MSC	  treated,	  4	  controls	  
Liver	  recipients	  
MSC+	  (n=10)	   MSC-­‐	  (n=10)	   P	  
Age	  (years)	   62.5	  (47-­‐74)	   58	  (52-­‐69)	   0.516	  
Male/Female	  	   8/2	   7/3	   1	  
Lab	  MELD	   16.5	  (6-­‐29)	   15	  (8-­‐38)	   0.491	  




5	   5	  
NASH	   3	   0	  
HCC	   2	   5	  
Median	  (Ranges)	  or	  n	  	  (Mann	  Whitney	  or	  Fischer	  test)	  
Liver	  donors	  &	  Transplanta2ons	  
MSC+	  group	  (n=10)	   Control	  group	  (n=10)	   P	  
Age	  (years)	   57	  (17-­‐77)	   54	  (18-­‐79)	   0.985	  
Male/Female	  	   4/6	   6/4	   0.656	  
CPR	  (Y/N)	   4/6	   3/7	   1	  
Donor	  type	  (DBD/DCD)	   4/6	   5/5	   1	  
BMI	  (kg/m2)	   24	  (21-­‐31)	   25	  (22-­‐29)	   0.510	  
Intensive	  care	  stay	  (days)	   4	  (1-­‐75)	   6.5	  (2-­‐29)	   0.401	  
Urinary	  output	  (mL/h)	   82	  (7-­‐160)	   127.5	  (47-­‐357)	   0.096	  
Pressors	  (Y/N)	   5/5	   6/4	   1	  
Na	  (mmol/L)	   144	  (133-­‐155)	   144.5	  (141-­‐160)	   0.445	  
Total	  bilirubin	  (mg/dL)	   0.35	  (0.30-­‐1.59)	   0.32	  (0.15-­‐0.85)	   0.668	  
AST	  (U/L)	   38	  (23-­‐190)	   48.5	  (26-­‐91)	   0.615	  

















Median	  (Ranges)	  or	  n	  	  (Mann	  Whitney	  or	  Fischer	  test)	  
MSC	  injec2on	  in	  LT	  recipients	  
Per	  protocol	   Study	  (Median)	  (IQR;	  Ranges)	  
MSC	  Injec2on	  day	   day	  3	  +/-­‐	  2	   3	  (3-­‐3.25;	  2-­‐5)	  
Dose	  MSC	  (106/kg)	   1.5-­‐3	   2.1	  (2.0-­‐2.4;	  1.9-­‐2.7)	  
Injec2on	  volume	  (ml)	   342	  (322-­‐469;	  306-­‐614)	  
Injec2on	  dura2on	  (min)	   25	  (16.2-­‐40;	  11-­‐60)	  
Median	  (IQR;	  Ranges)	  
Infusional	  toxicity	  
Pre	  Infusion	   15	  min	   End	  of	  infusion	   P	  
Body	  temperature	  (°C)	   36.0	  (35.4-­‐37.7)	   36.3	  (35-­‐36.9)	   36.2	  (35.5-­‐37)	   0.869	  
Mean	  PA	  (mmHg)	   103.3	  (87-­‐124)	   107	  (84-­‐119.5)	   106	  (94-­‐115)	   0.830	  
NI	  O2	  satura2on	   99	  (93-­‐100)	   100	  (92-­‐100)	   97.5	  (93-­‐100)	   0.670	  
Median	  (Ranges)	  (Friedman	  test	  &	  ANOVA)	  
-­‐  No	  hepa2c	  artery	  or	  portal	  vein	  thrombosis	  
-­‐  No	  sign	  of	  pulmonary	  embolism	  
-­‐  No	  post	  infusional	  intuba2on	  
-­‐  No	  anaphylac2c	  reac2on,	  no	  skin	  reac2on	  
-­‐  No	  increase	  of	  30	  days	  mortality	  	  




•  MSC	  have	  to	  be	  thawed	  and	  infused	  within	  one	  hour	  
-­‐	  problems	  for	  intra	  opera2ve	  infusion	  
-­‐	  24/7	  open	  GMP	  lab	  
	  
•  Next	  step?	  
-­‐	  2	  injec2ons	  	  ?	  
•  Mul2center	  blinded	  phase	  3	  study	  ?	  
•  Any	  idea	  or	  collabora2on	  is	  welcome	  
•  Ac2ve	  MISOT	  par2cipa2on?	  
Thanks	  to:	  
•  Hematology	  &	  LTCG	  
-­‐	  Pr	  Y	  Beguin,	  Pr	  F	  Baron,	  Dr	  E	  Baudoux,	  Mrs	  C	  Lechanteur	  
•  Surgery	  &	  Transplanta2on	  
-­‐	  Pr	  O	  Detry,	  Pr	  A	  Deroover,	  Dr	  N	  Meurisse,	  Mrs	  MH	  Delbouille,	  Dr	  Vandermeulen	  
•  Nephrology	  
-­‐	  Dr	  L	  Weekers,	  Dr	  C	  Bonvoisin,	  Dr	  F	  Jouret,	  Dr	  P	  Erpicum	  
•  Pathology	  












 Immunosuppressive therapy 
6 clinical trials 
4 in bone marrow transplantation 
1 in liver/kidney transplantation 
1 in auto-immune diseases 
ALLOGENEIC MSC 























Central production facility - 
LTCG Liège 
6 clinical trials 
